Hold AMGN; defer new entries until $393-$401 pullback or $412 breakout confirmation with volume >3M shares
The debate resolves cleanly to Hold. The aggressive analyst's upside thesis is anchored in a misleading PEG (dividing spot by an unvalidated 49% forward EPS estimate) and a speculative 440-460 target that the technical framework does not support — measured upside from a $412 breakout maps to $420-$425 (R2 resistance), not $460. The conservative analyst is right that the 75% volume contraction on the August 7 new high (1.46M vs. 5.75M on August 5), the intraday rejection at $411.60 against the $412.01 upper Bollinger Band, and RSI at 72 collectively signal buyer exhaustion rather than institutional coiling. The Q2 fundamentals are genuinely strong (+10% YoY revenue, +12.3% EPS surprise, $1B guide-up, 35.5% operating margins, $8.65B FCF), and the macro setup (8% recession odds, soft-landing consensus, 86% no-cut pricing through 2026) is structurally favorable for a 0.41-beta defensive compounder — these are the reasons to stay long, not to chase highs. The unquantified Tavneos regulatory review and cybersecurity breach are real overhangs that justify a discount on entry, not a fundamental exit. The neutral analyst's correction to the trader's plan is decisive: the pullback-to-$393-$401 trigger must be paired with a confirmed breakout trigger above $412 on volume >3M shares, otherwise the framework repeats the MSFT failure mode of optimizing for a trade that never arrives. The final framework: Hold existing positions, tighten trailing stop to $393 (10 EMA) for tactical risk, defer new entries until either a $393-$401 retest or a $412 breakout confirmation on volume, and reassess at Q3 earnings (late October / early November 2026) when forward EPS revisions will validate or invalidate the 49% consensus growth assumption.
| Position | Action |
|---|---|
| Pullback entry to $393-$401 zone (10 EMA to recent support) | Size at 50-75% of full allocation |
AMGN at $410.95 is a compelling risk-adjusted opportunity in large-cap biopharma combining Q2 earnings acceleration, technically confirmed uptrend, mechanical debt deleveraging, and significant forward earnings upside—all supported by macro tailwinds favoring defensive healthcare with growth optionality.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 72.10 | bearish |
| MACD Line | 12.01 | bullish |
| MACD Signal | 9.26 | bullish |
| MACD Histogram | +2.75 | bullish |
| 10 EMA | $393.41 | bullish |
| 50 SMA | $361.98 | bullish |
| 200 SMA | $343.38 | bullish |
| Bollinger Upper Band | $412.01 | neutral |
| Bollinger Middle Band | $378.91 | neutral |
| Bollinger Lower Band | $345.82 | neutral |
| ATR (14) | $11.86 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Technical setup is a picture-perfect uptrend with all major indicators confirming bullish momentum
↩ rebuts: “Bear rebuttal: 'But it's pressing the upper Bollinger Band at $412'”
· concedes: Tavneos data review is a real concern (administrative process, not forced label change); Cyber breach is a real concern (HIPAA fines, reputational risk, but easily absorbed by $90B+ asset base and $12B cash); MariTide is a binary outcome with Phase 3 risk; Polymarket pricing 86% probability of NO 2026 Fed cuts is already in run-rate
AMGN at $410.95 is a sell or strict hold—the stock has already priced in all known catalysts, technical setup is extended with bearish divergences, balance sheet remains leveraged at $45.3B net debt, and forward EPS estimates implying +49% growth are unrealistic given ~5.6% revenue guidance.
· concedes: Interest coverage at 6.3x is adequate for now; Q1'26 operating margin of 30.9% is an improvement over 2024's 27.6%; FCF generation of $8.1B provides some balance sheet flexibility; $12B cash position can absorb some tail risk costs; Technical uptrend remains intact in the medium term
→ vs conservative: The conservative analyst is managing for downside they can see rather than positioning for upside the market has not yet priced; waiting for 393-401 pullback is chasing a moving target while risking missing breakout continuation to 420, 425, or 440
→ vs conservative: The conservative analyst frames 4-5 percent downside versus 2-3 percent upside as unfavorable asymmetry, but ignores the probability distribution; odds favor continuation 60-70 percent given the momentum thrust from a fresh breakout with $1 billion guidance raise
→ vs neutral: Tavneos review and cybersecurity breach are already in the price; institutions are not selling into these headlines, they are accumulating through them; if these were existential risks, MACD would not be expanding and price would not be pressing against upper band
→ vs conservative: The conservative analyst penalizes AMGN for being too good; 'stretched operating leverage assumptions' argument ignores that Q2 already validated the trajectory with 12.3 percent EPS beat and 10 percent top-line beat
→ vs conservative: The conservative analyst's 'unfavorable asymmetry' assumes coin flip risk-reward when actual odds favor continuation; 10 EMA at 393.41 is rising and will be closer to 396-398 by the time price pulls back there
→ vs neutral: If existential risks existed, distribution patterns would be visible; instead seeing accumulation patterns with MACD expanding and price coiling against upper band at 412.01
| neutral |
| Latest Close | $410.95 | bullish |
| May 2026 Swing Low | ~$321.42 | bullish |
| Gain from May Low | ~+27.9% | bullish |
| Breakout Volume (2026-08-05) | 5,750,700 shares | bullish |
Support: 401.07 · 393.41 · 378.91 · 361.98 · 345.82 | Resistance: 412.01 · 420 · 425
AMGN exhibits a powerful confirmed uptrend that has accelerated into overbought territory, with the stock closing at a fresh recent high of $410.95 on 2026-08-07 after a ~28% rally from the May swing low. All major moving averages are bullishly stacked (price > 10 EMA > 50 SMA > 200 SMA) with golden cross regime intact, MACD momentum is positive and expanding (+2.75 histogram), and RSI sits at 72.1 (overbought but not extreme). However, price has touched the upper Bollinger Band at $412.01 and is trading at a late-stage impulse, creating poor risk/reward for new entries at current levels. The recommended action is HOLD for existing longs with trailing stops near $387 (2× ATR) or $393 (10 EMA), while new capital should await either a pullback to $393/$379 or a confirmed daily close above $412 on strong volume.
Market Capitalization
$222.32 billion
Share Price (52-wk range)
$269.77 – $411.60
50-Day Average
$356.69
200-Day Average
$344.25
P/E Ratio (TTM)
25.51x
Forward P/E
17.12x
PEG Ratio
2.14
Price/Book
19.01x
EPS (TTM)
$16.11
Forward EPS
$24.01
Dividend Yield
2.49%
Beta
0.41
TTM Revenue
$38.10B
TTM Gross Profit
$27.39B
TTM Gross Margin
71.9%
TTM EBITDA
$17.27B
TTM EBITDA Margin
45.3%
TTM Net Income
$8.74B
TTM Net Margin
22.95%
TTM Operating Margin
35.5%
Return on Equity (ROE)
91.5%
Return on Assets (ROA)
8.7%
Free Cash Flow (TTM)
$8.65B
FCF Margin
22.7%
2025 Revenue
$36,751M
2024 Revenue
$33,424M
2025 Net Income
$7,711M
2024 Net Income
$4,090M
2025 Diluted EPS
$14.23
2025 Gross Margin
67.2%
2025 Operating Margin
24.7%
2025 R&D
$7,272M
2025 EBITDA
$16,898M
Total Debt
$57,323M
Net Debt
$45,285M
Long-Term Debt
$51,886M
Cash & Equivalents
$12,038M
Stockholders' Equity
$9,190M
Goodwill & Intangibles
$40,053M
Tangible Book Value
-$30,863M
D/E Ratio
490%
Current Ratio
1.37
Working Capital
$6,520M
2025 Dividends Paid
$5,124M
2025 CapEx
$1,858M
2025 Free Cash Flow
$8,100M
2025 Net Debt Repayment
$5,000M
Q1'26 Revenue
$8,618M
Q1'26 Gross Margin
68.2%
Q1'26 Operating Margin
30.9%
Q1'26 Net Income
$1,819M
Q1'26 Diluted EPS
$3.34
Q1'26 Free Cash Flow
$1,477M
Q3'25 Net Income
$3,216M
Q3'25 Diluted EPS
$5.93
2022 Revenue
$26,323M
Horizon Acquisition Cost
$27.7B
Strengths
Concerns
Amgen is a mega-cap ($222B) biotechnology company with TTM revenue of $38.1B and strong profitability (45.3% EBITDA margin, 22.95% net margin). The $27.7B Horizon Therapeutics acquisition (Oct 2023) drove 2024 revenue growth of 18.6% and 2025 revenue of $36.8B (+10% YoY), but has resulted in significant leverage ($57.3B total debt, 490% D/E) and margin compression (operating margin declined from 36.3% in 2022 to 24.7% in 2025). The investment thesis centers on the ~49% forward EPS expansion consensus expects (TTM $16.11 to forward $24.01), supported by MariTide obesity pipeline, Horizon synergies, and ongoing deleveraging ($5B repaid in 2025). With a 2.49% dividend yield, 0.41 beta, and attractive 17.1x forward P/E, Amgen offers defensive exposure with meaningful earnings upside optionality if pipeline programs succeed.